These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1023 related articles for article (PubMed ID: 19711514)
1. Detailed examination of HLA antibody development on renal allograft failure and function. Zhu L; Lee PC; Everly MJ; Terasaki PI Clin Transpl; 2008; ():171-87. PubMed ID: 19711514 [TBL] [Abstract][Full Text] [Related]
2. HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss. Lee PC; Zhu L; Terasaki PI; Everly MJ Transplantation; 2009 Aug; 88(4):568-74. PubMed ID: 19696641 [TBL] [Abstract][Full Text] [Related]
3. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation. Lee PC; Ozawa M Clin Transpl; 2007; ():219-26. PubMed ID: 18642453 [TBL] [Abstract][Full Text] [Related]
4. Impact of human leukocyte antigen matching and recipients' panel reactive antibodies on two-year outcome in presensitized renal allograft recipients. Meng HL; Jin XB; Li XT; Wang HW; Lü JJ Chin Med J (Engl); 2009 Feb; 122(4):420-6. PubMed ID: 19302748 [TBL] [Abstract][Full Text] [Related]
5. Donor-specific HLA antibodies in chronic renal allograft rejection: a prospective trial with a four-year follow-up. Lachmann N; Terasaki PI; Schönemann C Clin Transpl; 2006; ():171-99. PubMed ID: 18365377 [TBL] [Abstract][Full Text] [Related]
6. Long-term post transplant alloantibody monitoring: a single center experience. Ntokou IS; Boletis JN; Apostolaki M; Vrani V; Zavos G; Kostakis A; Iniotaki A Clin Transpl; 2011; ():341-50. PubMed ID: 22755429 [TBL] [Abstract][Full Text] [Related]
7. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Lachmann N; Terasaki PI; Budde K; Liefeldt L; Kahl A; Reinke P; Pratschke J; Rudolph B; Schmidt D; Salama A; Schönemann C Transplantation; 2009 May; 87(10):1505-13. PubMed ID: 19461487 [TBL] [Abstract][Full Text] [Related]
8. Clinical significance of post kidney transplant de novo DSA in otherwise stable grafts. Cooper JE; Gralla J; Chan L; Wiseman AC Clin Transpl; 2011; ():359-64. PubMed ID: 22755431 [TBL] [Abstract][Full Text] [Related]
9. Clinical and anti-HLA antibody profile of nine renal transplant recipients with failed grafts: donor-specific and non-donor-specific antibody development. Rebellato LM; Ozawa M; Verbanac KM; Catrou P; Haisch CE; Terasaki PI Clin Transpl; 2006; ():241-53. PubMed ID: 18365382 [TBL] [Abstract][Full Text] [Related]
10. Longitudinal testing of 266 renal allograft patients for HLA and MICA antibodies: Greenville experience. Ozawa M; Rebellato LM; Terasaki PI; Tong A; Briley KP; Catrou P; Haisch CE Clin Transpl; 2006; ():265-90. PubMed ID: 18365384 [TBL] [Abstract][Full Text] [Related]
11. Donor-specific HLA alloantibodies: long-term impact on cardiac allograft vasculopathy and mortality after heart transplant. Kaczmarek I; Deutsch MA; Kauke T; Beiras-Fernandez A; Schmoeckel M; Vicol C; Sodian R; Reichart B; Spannagl M; Ueberfuhr P Exp Clin Transplant; 2008 Sep; 6(3):229-35. PubMed ID: 18954302 [TBL] [Abstract][Full Text] [Related]
12. Long-term follow up for anti-HLA donor specific antibodies postrenal transplantation: high immunogenicity of HLA class II graft molecules. Ntokou IS; Iniotaki AG; Kontou EN; Darema MN; Apostolaki MD; Kostakis AG; Boletis JN Transpl Int; 2011 Nov; 24(11):1084-93. PubMed ID: 21848902 [TBL] [Abstract][Full Text] [Related]
14. Longitudinal testing of seventy-six renal allograft patients for HLA antibodies: Maastricht experience. van den Berg-Loonen EM; Terasaki P; Kohanof S; Christiaans MH Clin Transpl; 2006; ():305-22. PubMed ID: 18365386 [TBL] [Abstract][Full Text] [Related]
15. Intact HLA not beta2m-free heavy chain-specific HLA class I antibodies are predictive of graft failure. Cai J; Terasaki PI; Anderson N; Lachmann N; Schönemann C Transplantation; 2009 Jul; 88(2):226-30. PubMed ID: 19623018 [TBL] [Abstract][Full Text] [Related]
16. Clinical relevance of pre and post-transplant immune markers in kidney allograft recipients: anti-HLA and MICA antibodies and serum levels of sCD30 and sMICA. Solgi G; Furst D; Mytilineos J; Pourmand G; Amirzargar AA Transpl Immunol; 2012 Mar; 26(2-3):81-7. PubMed ID: 22182633 [TBL] [Abstract][Full Text] [Related]
17. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Everly MJ; Rebellato LM; Haisch CE; Ozawa M; Parker K; Briley KP; Catrou PG; Bolin P; Kendrick WT; Kendrick SA; Harland RC; Terasaki PI Transplantation; 2013 Feb; 95(3):410-7. PubMed ID: 23380861 [TBL] [Abstract][Full Text] [Related]
18. Impact of HLA antibodies on graft survival in long-term renal recipients with functional grafts. Zeng Y; Liu Z; Liu Y; Fan Y; Guo Y; Qiu J Urol Int; 2014; 92(3):328-33. PubMed ID: 24480999 [TBL] [Abstract][Full Text] [Related]
19. Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome. Worthington JE; Martin S; Al-Husseini DM; Dyer PA; Johnson RW Transplantation; 2003 Apr; 75(7):1034-40. PubMed ID: 12698094 [TBL] [Abstract][Full Text] [Related]
20. De novo donor specific antibodies and patient outcomes in renal transplantation. DeVos JM; Patel SJ; Burns KM; Dilioglou S; Gaber LW; Knight RJ; Gaber AO; Land GA Clin Transpl; 2011; ():351-8. PubMed ID: 22755430 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]